Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy

被引:83
作者
Schaafsma, Evelien [1 ,2 ]
Fugle, Chloe M. [2 ]
Wang, Xiaofeng [1 ]
Cheng, Chao [2 ,3 ,4 ,5 ]
机构
[1] Dartmouth Coll, Dept Mol & Syst Biol, Hanover, NH 03755 USA
[2] Geisel Sch Med Dartmouth, Dept Biomed Data Sci, Lebanon, NH 03755 USA
[3] Baylor Coll Med, Dept Med, Houston, TX 77030 USA
[4] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA
[5] Baylor Coll Med, Inst Clin & Translat Res, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
RENAL-CELL CARCINOMA; CLASS-I EXPRESSION; LUNG-CANCER; SOMATIC MUTATIONS; MESSENGER-RNA; ANTIGEN; RESPONSES; ESCAPE; TUMORS; SUSCEPTIBILITY;
D O I
10.1038/s41416-021-01400-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The function of major histocompatibility complex (MHC) molecules is to bind peptide fragments derived from genomic mutations or pathogens and display them on the cell surface for recognition by cognate T cells to initiate an immune response. Methods In this study, we provide a comprehensive investigation of HLA gene expression in a pan-cancer manner involving 33 cancer types. We utilised gene expression data from several databases and immune checkpoint blockade-treated patient cohorts. Results We show that MHC expression varies strongly among cancer types and is associated with several genomic and immunological features. While immune cell infiltration was generally higher in tumours with higher HLA gene expression, CD4+ T cells showed significantly different correlations among cancer types, separating them into two clusters. Furthermore, we show that increased HLA gene expression is associated with prolonged survival in the majority of cancer types. Lastly, HLA gene expression is associated with patient response to immune checkpoint blockade, which is especially prominent for HLA class II expression in tumour biopsies taken during treatment. Conclusion We show that HLA gene expression is an important feature of tumour biology that has significant impact on patient prognosis.
引用
收藏
页码:422 / 432
页数:11
相关论文
共 63 条
[1]   Plasma human leukocyte antigen-G (HLA-G) in patients with thyroid cancer [J].
Akin, Murat ;
Aral, Latife Arzu ;
Yavuz, Aydin ;
Karabacak, Harun ;
Dikmen, Kursat ;
Bostanci, Hasan .
TURKISH JOURNAL OF MEDICAL SCIENCES, 2017, 47 (04) :1263-1266
[2]   Levels of soluble HLA-I and b2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy [J].
Albitar, M. ;
Johnson, M. ;
Do, K. A. ;
Day, A. ;
Jilani, I. ;
Pierce, S. ;
Estey, E. ;
Kantarjian, H. ;
Keating, M. ;
Verstovsek, S. ;
O'Brien, S. ;
Giles, F. J. .
LEUKEMIA, 2007, 21 (03) :480-488
[3]   MHC-II neoantigens shape tumour immunity and response to immunotherapy [J].
Alspach, Elise ;
Lussier, Danielle M. ;
Miceli, Alexander P. ;
Kizhvatov, Ilya ;
DuPage, Michel ;
Luoma, Adrienne M. ;
Meng, Wei ;
Lichti, Cheryl F. ;
Esaulova, Ekaterina ;
Vomund, Anthony N. ;
Runci, Daniele ;
Ward, Jeffrey P. ;
Gubin, Matthew M. ;
Medrano, Ruan F. V. ;
Arthur, Cora D. ;
White, J. Michael ;
Sheehan, Kathleen C. F. ;
Chen, Alex ;
Wucherpfennig, Kai W. ;
Jacks, Tyler ;
Unanue, Emil R. ;
Artyomov, Maxim N. ;
Schreiber, Robert D. .
NATURE, 2019, 574 (7780) :696-+
[4]   Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity [J].
Anagnostou, Valsamo ;
Yarchoan, Mark ;
Hansen, Aaron R. ;
Wang, Hao ;
Verde, Franco ;
Sharon, Elad ;
Collyar, Deborah ;
Chow, Laura Q. M. ;
Forde, Patrick M. .
CLINICAL CANCER RESEARCH, 2017, 23 (17) :4959-4969
[5]   The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses [J].
Aptsiauri, Natalia ;
Ruiz-Cabello, Francisco ;
Garrido, Federico .
CURRENT OPINION IN IMMUNOLOGY, 2018, 51 :123-132
[6]  
Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]
[7]   Plasma levels of soluble HLA-G and cytokines in papillary thyroid carcinoma before and after thyroidectomy [J].
Bertol, Bruna C. ;
de Araujo, Jessica N. G. ;
Sadissou, Ibrahim A. ;
Sonon, Paulin ;
Dias, Fabricio C. ;
Bortolin, Raul H. ;
de Figueiredo-Feitosa, Nathalie L. ;
de Freitas, Luiz C. Conti ;
Tarrapp, Sheila R. de Miranda Henrique ;
Ramos, Carlos C. de Oliveira ;
Luchessi, Andre D. ;
de Freitas, Janaina C. O. C. ;
Maciel, Lea M. Z. ;
Silbiger, Vivian N. ;
Donadi, Eduardo A. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2020, 74 (10)
[8]   CD4+ T cell help in cancer immunology and immunotherapy [J].
Borst, Jannie ;
Ahrends, Tomasz ;
Babala, Nikolina ;
Melief, Cornelis J. M. ;
Kastenmueller, Wolfgang .
NATURE REVIEWS IMMUNOLOGY, 2018, 18 (10) :635-647
[9]   HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C [J].
Braud, VM ;
Allan, DSJ ;
O'Callaghan, CA ;
Söderström, K ;
D'Andrea, A ;
Ogg, GS ;
Lazetic, S ;
Young, NT ;
Bell, JI ;
Phillips, JH ;
Lanier, LL ;
McMichael, AJ .
NATURE, 1998, 391 (6669) :795-799
[10]   HLA-G: from biology to clinical benefits [J].
Carosella, Edgardo D. ;
Moreau, Philippe ;
LeMaoult, Joeel ;
Rouas-Freiss, Nathalie .
TRENDS IN IMMUNOLOGY, 2008, 29 (03) :125-132